Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today

Two of the hottest healthcare stocks in recent years have been Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY). The former has risen by 400% in the past five years, while the latter is up 67%. If not for the steep sell-off in Novo Nordisk's value this year, however, its gains would be far more significant.But these stocks still look underrated. While many investors may be reevaluating how much growth may be ahead for these two GLP-1 drugmakers, both seem to be underestimated. If you haven't invested in either of these companies yet, here's why you may want to consider doing so.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool